AXL is an oncotarget in human colorectal cancer

Erika Martinelli; Giulia Martini; Claudia Cardone; Teresa Troiani; Giuseppina Liguori; Donata Vitagliano; Stefania Napolitano; Floriana Morgillo; Barbara Rinaldi; Rosa Marina Melillo; Federica Liotti; Anna Nappi; Roberto Bianco; Liberato Berrino; Loreta Pia Ciuffreda; Davide Ciardiello; Vincenzo Iaffaioli; Gerardo Botti; Fiorella Ferraiolo; Fortunato Ciardiello

doi:10.18632/oncotarget.3962

AXL is an oncotarget in human colorectal cancer

Erika Martinelli, Giulia Martini, Claudia Cardone, Teresa Troiani, Giuseppina Liguori, Donata Vitagliano, Stefania Napolitano, Floriana Morgillo, Barbara Rinaldi, Rosa Marina Melillo, Federica Liotti, Anna Nappi, Roberto Bianco, Liberato Berrino, Loreta Pia Ciuffreda, Davide Ciardiello, Vincenzo Iaffaioli, Gerardo Botti, Fiorella Ferraiolo, Fortunato Ciardiello

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article › peer-review

Abstract

AXL is a tyrosine kinase receptor activated by GAS6 and regulates cancer cell proliferation migration and angiogenesis. We studied AXL as new therapeutic target in colorectal cancer (CRC). Expression and activation of AXL and GAS6 were evaluated in a panel of human CRC cell lines. AXL gene silencing or pharmacologic inhibition with foretinib suppressed proliferation, migration and survival in CRC cells. In an orthotopic colon model of human HCT116 CRC cells overexpressing AXL, foretinib treatment caused significant inhibition of tumour growth and peritoneal metastatic spreading. AXL and GAS6 overexpression by immunohistochemistry (IHC) were found in 76,7% and 73.5%, respectively, of 223 human CRC specimens, correlating with less differentiated histological grading. GAS6 overexpression was associated with nodes involvement and tumour stage. AXL gene was found amplified by Fluorescence in situ hybridization (FISH) in 8/146 cases (5,4%) of CRC samples. Taken together, AXL inhibition could represent a novel therapeutic approach in CRC.

Original language	English
Pages (from-to)	23281-23296
Number of pages	16
Journal	Oncotarget
Volume	6
Issue number	27
DOIs	https://doi.org/10.18632/oncotarget.3962
Publication status	Published - 2015

Keywords

AXL
Colorectal cancer
FISH
Foretinib
GAS6

ASJC Scopus subject areas

Oncology

Access to Document

10.18632/oncotarget.3962

Fingerprint Dive into the research topics of 'AXL is an oncotarget in human colorectal cancer'. Together they form a unique fingerprint.

Cite this

Martinelli, E., Martini, G., Cardone, C., Troiani, T., Liguori, G., Vitagliano, D., Napolitano, S., Morgillo, F., Rinaldi, B., Melillo, R. M., Liotti, F., Nappi, A., Bianco, R., Berrino, L., Ciuffreda, L. P., Ciardiello, D., Iaffaioli, V., Botti, G., Ferraiolo, F., & Ciardiello, F. (2015). AXL is an oncotarget in human colorectal cancer. Oncotarget, 6(27), 23281-23296. https://doi.org/10.18632/oncotarget.3962

AXL is an oncotarget in human colorectal cancer. / Martinelli, Erika; Martini, Giulia; Cardone, Claudia; Troiani, Teresa; Liguori, Giuseppina; Vitagliano, Donata; Napolitano, Stefania; Morgillo, Floriana; Rinaldi, Barbara; Melillo, Rosa Marina; Liotti, Federica; Nappi, Anna; Bianco, Roberto; Berrino, Liberato; Ciuffreda, Loreta Pia; Ciardiello, Davide; Iaffaioli, Vincenzo; Botti, Gerardo; Ferraiolo, Fiorella; Ciardiello, Fortunato.

In: Oncotarget, Vol. 6, No. 27, 2015, p. 23281-23296.

Research output: Contribution to journal › Article › peer-review

Martinelli, E, Martini, G, Cardone, C, Troiani, T, Liguori, G, Vitagliano, D, Napolitano, S, Morgillo, F, Rinaldi, B, Melillo, RM, Liotti, F, Nappi, A, Bianco, R, Berrino, L, Ciuffreda, LP, Ciardiello, D, Iaffaioli, V, Botti, G, Ferraiolo, F & Ciardiello, F 2015, 'AXL is an oncotarget in human colorectal cancer', Oncotarget, vol. 6, no. 27, pp. 23281-23296. https://doi.org/10.18632/oncotarget.3962

Martinelli, Erika ; Martini, Giulia ; Cardone, Claudia ; Troiani, Teresa ; Liguori, Giuseppina ; Vitagliano, Donata ; Napolitano, Stefania ; Morgillo, Floriana ; Rinaldi, Barbara ; Melillo, Rosa Marina ; Liotti, Federica ; Nappi, Anna ; Bianco, Roberto ; Berrino, Liberato ; Ciuffreda, Loreta Pia ; Ciardiello, Davide ; Iaffaioli, Vincenzo ; Botti, Gerardo ; Ferraiolo, Fiorella ; Ciardiello, Fortunato. / AXL is an oncotarget in human colorectal cancer. In: Oncotarget. 2015 ; Vol. 6, No. 27. pp. 23281-23296.

@article{6da15f9184254891b25ec0d0ca4b8c0f,

title = "AXL is an oncotarget in human colorectal cancer",

abstract = "AXL is a tyrosine kinase receptor activated by GAS6 and regulates cancer cell proliferation migration and angiogenesis. We studied AXL as new therapeutic target in colorectal cancer (CRC). Expression and activation of AXL and GAS6 were evaluated in a panel of human CRC cell lines. AXL gene silencing or pharmacologic inhibition with foretinib suppressed proliferation, migration and survival in CRC cells. In an orthotopic colon model of human HCT116 CRC cells overexpressing AXL, foretinib treatment caused significant inhibition of tumour growth and peritoneal metastatic spreading. AXL and GAS6 overexpression by immunohistochemistry (IHC) were found in 76,7% and 73.5%, respectively, of 223 human CRC specimens, correlating with less differentiated histological grading. GAS6 overexpression was associated with nodes involvement and tumour stage. AXL gene was found amplified by Fluorescence in situ hybridization (FISH) in 8/146 cases (5,4%) of CRC samples. Taken together, AXL inhibition could represent a novel therapeutic approach in CRC.",

keywords = "AXL, Colorectal cancer, FISH, Foretinib, GAS6",

author = "Erika Martinelli and Giulia Martini and Claudia Cardone and Teresa Troiani and Giuseppina Liguori and Donata Vitagliano and Stefania Napolitano and Floriana Morgillo and Barbara Rinaldi and Melillo, {Rosa Marina} and Federica Liotti and Anna Nappi and Roberto Bianco and Liberato Berrino and Ciuffreda, {Loreta Pia} and Davide Ciardiello and Vincenzo Iaffaioli and Gerardo Botti and Fiorella Ferraiolo and Fortunato Ciardiello",

year = "2015",

doi = "10.18632/oncotarget.3962",

language = "English",

volume = "6",

pages = "23281--23296",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "27",

}

TY - JOUR

T1 - AXL is an oncotarget in human colorectal cancer

AU - Martinelli, Erika

AU - Martini, Giulia

AU - Cardone, Claudia

AU - Troiani, Teresa

AU - Liguori, Giuseppina

AU - Vitagliano, Donata

AU - Napolitano, Stefania

AU - Morgillo, Floriana

AU - Rinaldi, Barbara

AU - Melillo, Rosa Marina

AU - Liotti, Federica

AU - Nappi, Anna

AU - Bianco, Roberto

AU - Berrino, Liberato

AU - Ciuffreda, Loreta Pia

AU - Ciardiello, Davide

AU - Iaffaioli, Vincenzo

AU - Botti, Gerardo

AU - Ferraiolo, Fiorella

AU - Ciardiello, Fortunato

PY - 2015

Y1 - 2015

N2 - AXL is a tyrosine kinase receptor activated by GAS6 and regulates cancer cell proliferation migration and angiogenesis. We studied AXL as new therapeutic target in colorectal cancer (CRC). Expression and activation of AXL and GAS6 were evaluated in a panel of human CRC cell lines. AXL gene silencing or pharmacologic inhibition with foretinib suppressed proliferation, migration and survival in CRC cells. In an orthotopic colon model of human HCT116 CRC cells overexpressing AXL, foretinib treatment caused significant inhibition of tumour growth and peritoneal metastatic spreading. AXL and GAS6 overexpression by immunohistochemistry (IHC) were found in 76,7% and 73.5%, respectively, of 223 human CRC specimens, correlating with less differentiated histological grading. GAS6 overexpression was associated with nodes involvement and tumour stage. AXL gene was found amplified by Fluorescence in situ hybridization (FISH) in 8/146 cases (5,4%) of CRC samples. Taken together, AXL inhibition could represent a novel therapeutic approach in CRC.

AB - AXL is a tyrosine kinase receptor activated by GAS6 and regulates cancer cell proliferation migration and angiogenesis. We studied AXL as new therapeutic target in colorectal cancer (CRC). Expression and activation of AXL and GAS6 were evaluated in a panel of human CRC cell lines. AXL gene silencing or pharmacologic inhibition with foretinib suppressed proliferation, migration and survival in CRC cells. In an orthotopic colon model of human HCT116 CRC cells overexpressing AXL, foretinib treatment caused significant inhibition of tumour growth and peritoneal metastatic spreading. AXL and GAS6 overexpression by immunohistochemistry (IHC) were found in 76,7% and 73.5%, respectively, of 223 human CRC specimens, correlating with less differentiated histological grading. GAS6 overexpression was associated with nodes involvement and tumour stage. AXL gene was found amplified by Fluorescence in situ hybridization (FISH) in 8/146 cases (5,4%) of CRC samples. Taken together, AXL inhibition could represent a novel therapeutic approach in CRC.

KW - AXL

KW - Colorectal cancer

KW - FISH

KW - Foretinib

KW - GAS6

UR - http://www.scopus.com/inward/record.url?scp=84943411277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943411277&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.3962

DO - 10.18632/oncotarget.3962

M3 - Article

AN - SCOPUS:84943411277

VL - 6

SP - 23281

EP - 23296

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 27

ER -